Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	23.04	28.36	34.81	29.43	39.14	43.84
Short-Term Investments	607.29	696.93	388.78	275.52	369.11	150.59
Cash & Short-Term Investments	630.34	725.28	423.6	304.95	408.25	194.42
Cash Growth	-21.44%	71.22%	38.91%	-25.30%	109.98%	201.98%
Receivables	0.09	0.7	2.63	0.35	0.17	1.8
Prepaid Expenses	17.98	21.18	5.47	12.39	2.42	1.62
Total Current Assets	648.4	747.16	431.69	317.69	410.84	197.84
Property, Plant & Equipment	7.51	8.24	6.64	7.75	6.52	7.26
Other Intangible Assets	27.19	27.19	27.19	27.19	27.19	30.69
Other Long-Term Assets	9.3	9.75	0.11	0.1	0.1	0.04
Total Assets	692.41	792.34	465.63	352.74	444.65	235.84
Accounts Payable	2.07	3.27	3.49	3.34	1.23	1.05
Accrued Expenses	28.42	33.84	22.03	12.84	12	8.46
Current Portion of Leases	1.54	1.45	1.61	1.45	1.75	1.33
Current Unearned Revenue	-	0.01	3.06	0.06	0.43	-
Other Current Liabilities	0.93	0.93	0.93	0.93	1.12	3.37
Total Current Liabilities	32.96	39.5	31.13	18.61	16.53	14.21
Long-Term Leases	1.5	2.36	0.93	2.59	1.3	2.15
Other Long-Term Liabilities	2.54	3.47	4.4	5.33	7.35	10.12
Total Liabilities	37	45.34	36.46	26.53	25.18	26.48
Common Stock	0.07	0.07	0.06	0.05	0.05	0.04
Additional Paid-In Capital	2,318	2,299	1,823	1,581	1,561	1,280
Retained Earnings	-1,666	-1,555	-1,397	-1,256	-1,144	-1,073
Comprehensive Income & Other	3.34	3.31	3.31	1.26	1.89	2.59
Shareholders' Equity	655.41	747.01	429.17	326.2	419.48	209.36
Total Liabilities & Equity	692.41	792.34	465.63	352.74	444.65	235.84
Total Debt	3.03	3.81	2.54	4.03	3.04	3.48
Net Cash (Debt)	627.31	721.47	421.06	300.92	405.21	190.94
Net Cash Growth	-21.58%	71.35%	39.92%	-25.74%	112.22%	214.43%
Net Cash Per Share	9.45	11.20	8.69	6.42	9.45	6.44
Filing Date Shares Outstanding	66.41	66.38	55.9	47.21	46.74	39.61
Total Common Shares Outstanding	66.39	66.37	55.88	47.2	46.73	39.6
Working Capital	615.44	707.66	400.57	299.08	394.31	183.64
Book Value Per Share	9.87	11.25	7.68	6.91	8.98	5.29
Tangible Book Value	628.22	719.82	401.98	299.01	392.29	178.67
Tangible Book Value Per Share	9.46	10.84	7.19	6.33	8.39	4.51
Machinery	-	17.39	16.01	15.26	14.51	14.61
Construction In Progress	-	0.14	0.79	0.5	0.63	0.34
Leasehold Improvements	-	10.29	9.65	9.61	9.53	10.1

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q